The Effect of Acute Loading with Selegiline and Selegiline with Levodopa on Blood Pressure and Plasma Norepinephrine Levels in Chronic Parkinsonian Patients
Selegiline, an irreversible inhibitor of monoamine oxidase B (MAO B), was introduced as a symptomatic treatment for Parkinson’s disease (PD) in the mid-1970s, with the intention of enhancing the effect of levodopa (LD).1–3
KeywordsOrthostatic Hypotension Multiple System Atrophy Pure Autonomic Failure Plasma Norepinephrine Level Supine Hypertension
Unable to display preview. Download preview PDF.
- 2.Lees AJ, Shaw KM, Kohout LT, et al. Deprenyl in Parkinson’s disease. Lancet 1997;2:791–5.Google Scholar
- 3.Streifler M, Vardi J, Borenstein N, et al. S. B-type Monoamine oxidase (M.A.O.) inhibitors in long-term levodopa treated Parkinsonism. A combined clinical trial with L-deprenyl. Curr Ther Res Clin Exp 1980;27:643–8.Google Scholar
- 6.Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1996;46:1470.Google Scholar
- 13.Goodman Gilman A, Goodman LS, Rail TW, et al, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 7th ed. New York: Macmillan Publishing Company, 1985:1786.Google Scholar